NASDAQ:NDRA

ENDRA Life Sciences Competitors

$2.28
-0.08 (-3.39 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.22
Now: $2.28
$2.41
50-Day Range
$2.02
MA: $2.50
$2.84
52-Week Range
$0.60
Now: $2.28
$3.10
Volume983,383 shs
Average Volume3.15 million shs
Market Capitalization$94.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6

Competitors

ENDRA Life Sciences (NASDAQ:NDRA) Vs. EDAP, EYES, BSGM, FONR, IRIX, and SLNO

Should you be buying NDRA stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to ENDRA Life Sciences, including Edap Tms (EDAP), Second Sight Medical Products (EYES), BioSig Technologies (BSGM), FONAR (FONR), IRIDEX (IRIX), and Soleno Therapeutics (SLNO).

ENDRA Life Sciences (NASDAQ:NDRA) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Risk and Volatility

ENDRA Life Sciences has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.

Valuation and Earnings

This table compares ENDRA Life Sciences and Edap Tms' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life Sciences$10,000.009,484.80$-13,310,000.00($2.34)-0.97
Edap Tms$50.23 million5.26$1.69 million$0.06151.00

Edap Tms has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for ENDRA Life Sciences and Edap Tms, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ENDRA Life Sciences0000N/A
Edap Tms00303.00

Edap Tms has a consensus target price of $12.50, suggesting a potential upside of 37.97%. Given Edap Tms' higher probable upside, analysts clearly believe Edap Tms is more favorable than ENDRA Life Sciences.

Profitability

This table compares ENDRA Life Sciences and Edap Tms' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ENDRA Life SciencesN/A-492.76%-288.58%
Edap Tms-4.03%-11.54%-5.78%

Institutional and Insider Ownership

2.8% of ENDRA Life Sciences shares are held by institutional investors. 9.6% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Edap Tms beats ENDRA Life Sciences on 8 of the 13 factors compared between the two stocks.

Second Sight Medical Products (NASDAQ:EYES) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Second Sight Medical Products and ENDRA Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Second Sight Medical ProductsN/A-977.63%-291.02%
ENDRA Life SciencesN/A-492.76%-288.58%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Second Sight Medical Products and ENDRA Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Second Sight Medical Products0000N/A
ENDRA Life Sciences0000N/A

Institutional & Insider Ownership

4.1% of Second Sight Medical Products shares are owned by institutional investors. Comparatively, 2.8% of ENDRA Life Sciences shares are owned by institutional investors. 67.5% of Second Sight Medical Products shares are owned by insiders. Comparatively, 9.6% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Second Sight Medical Products has a beta of 2.49, suggesting that its share price is 149% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Valuation & Earnings

This table compares Second Sight Medical Products and ENDRA Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Second Sight Medical Products$3.38 million56.68$-33,590,000.00($1.91)-4.31
ENDRA Life Sciences$10,000.009,484.80$-13,310,000.00($2.34)-0.97

ENDRA Life Sciences has lower revenue, but higher earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

BioSig Technologies (NASDAQ:BSGM) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Profitability

This table compares BioSig Technologies and ENDRA Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSig TechnologiesN/A-244.64%-213.88%
ENDRA Life SciencesN/A-492.76%-288.58%

Volatility and Risk

BioSig Technologies has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for BioSig Technologies and ENDRA Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSig Technologies0000N/A
ENDRA Life Sciences0000N/A

Institutional and Insider Ownership

18.3% of BioSig Technologies shares are owned by institutional investors. Comparatively, 2.8% of ENDRA Life Sciences shares are owned by institutional investors. 19.5% of BioSig Technologies shares are owned by insiders. Comparatively, 9.6% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares BioSig Technologies and ENDRA Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A
ENDRA Life Sciences$10,000.009,484.80$-13,310,000.00($2.34)-0.97

ENDRA Life Sciences has higher revenue and earnings than BioSig Technologies.

Summary

BioSig Technologies beats ENDRA Life Sciences on 5 of the 7 factors compared between the two stocks.

FONAR (NASDAQ:FONR) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Profitability

This table compares FONAR and ENDRA Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FONAR8.28%5.57%3.99%
ENDRA Life SciencesN/A-492.76%-288.58%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for FONAR and ENDRA Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FONAR0000N/A
ENDRA Life Sciences0000N/A

Earnings and Valuation

This table compares FONAR and ENDRA Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FONAR$85.69 million1.38$8.24 millionN/AN/A
ENDRA Life Sciences$10,000.009,484.80$-13,310,000.00($2.34)-0.97

FONAR has higher revenue and earnings than ENDRA Life Sciences.

Volatility and Risk

FONAR has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Institutional and Insider Ownership

62.1% of FONAR shares are owned by institutional investors. Comparatively, 2.8% of ENDRA Life Sciences shares are owned by institutional investors. 8.6% of FONAR shares are owned by insiders. Comparatively, 9.6% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

FONAR beats ENDRA Life Sciences on 7 of the 10 factors compared between the two stocks.

ENDRA Life Sciences (NASDAQ:NDRA) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares ENDRA Life Sciences and IRIDEX's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ENDRA Life SciencesN/A-492.76%-288.58%
IRIDEX-21.54%-38.60%-24.99%

Analyst Recommendations

This is a summary of current ratings and price targets for ENDRA Life Sciences and IRIDEX, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ENDRA Life Sciences0000N/A
IRIDEX00203.00

IRIDEX has a consensus price target of $6.50, indicating a potential downside of 12.28%. Given IRIDEX's higher possible upside, analysts clearly believe IRIDEX is more favorable than ENDRA Life Sciences.

Valuation & Earnings

This table compares ENDRA Life Sciences and IRIDEX's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life Sciences$10,000.009,484.80$-13,310,000.00($2.34)-0.97
IRIDEX$43.45 million2.65$-8,810,000.00($0.64)-11.58

IRIDEX has higher revenue and earnings than ENDRA Life Sciences. IRIDEX is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ENDRA Life Sciences has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Institutional and Insider Ownership

2.8% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 32.6% of IRIDEX shares are owned by institutional investors. 9.6% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 2.0% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

IRIDEX beats ENDRA Life Sciences on 8 of the 13 factors compared between the two stocks.

ENDRA Life Sciences (NASDAQ:NDRA) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares ENDRA Life Sciences and Soleno Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ENDRA Life SciencesN/A-492.76%-288.58%
Soleno TherapeuticsN/A-88.69%-51.63%

Analyst Recommendations

This is a summary of current ratings and price targets for ENDRA Life Sciences and Soleno Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ENDRA Life Sciences0000N/A
Soleno Therapeutics00303.00

Soleno Therapeutics has a consensus price target of $8.6667, indicating a potential upside of 610.38%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than ENDRA Life Sciences.

Valuation & Earnings

This table compares ENDRA Life Sciences and Soleno Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life Sciences$10,000.009,484.80$-13,310,000.00($2.34)-0.97
Soleno TherapeuticsN/AN/A$-30,770,000.00($0.70)-1.74

ENDRA Life Sciences has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ENDRA Life Sciences has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Institutional and Insider Ownership

2.8% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 55.4% of Soleno Therapeutics shares are owned by institutional investors. 9.6% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 74.9% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Soleno Therapeutics beats ENDRA Life Sciences on 7 of the 11 factors compared between the two stocks.


ENDRA Life Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Edap Tms logo
EDAP
Edap Tms
1.3$9.06-1.4%$264.03 million$50.23 million-151.00Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.24-1.8%$191.58 million$3.38 million-4.31Decrease in Short Interest
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.21-2.6%$133.84 millionN/A0.00News Coverage
FONR
FONAR
1.1$17.98-0.1%$117.84 million$85.69 million16.96
IRIDEX logo
IRIX
IRIDEX
0.9$7.41-1.2%$115.01 million$43.45 million-13.47
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.22-2.5%$97.26 millionN/A-1.61Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.82-1.1%$88.23 million$2.39 million-2.30Decrease in Short Interest
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.56-0.7%$40.58 million$1.50 million-1.00Analyst Upgrade
Increase in Short Interest
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.33-1.7%$32.18 million$5.51 million-0.11High Trading Volume
Increase in Short Interest
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.01-0.3%$31.13 million$6.57 million-0.01
STRR
Star Equity
0.1$3.21-2.8%$15.80 million$114.18 million-1.02
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.